🇪🇺 Inhaled loxapine 10 mg in European Union

EMA authorised Inhaled loxapine 10 mg on 20 February 2013

Marketing authorisation

EMA — authorised 20 February 2013

  • Application: EMEA/H/C/002400
  • Marketing authorisation holder: Ferrer Internacional S.A.
  • Local brand name: Adasuve
  • Indication: Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
  • Status: approved

Read official source →

Inhaled loxapine 10 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Inhaled loxapine 10 mg approved in European Union?

Yes. EMA authorised it on 20 February 2013.

Who is the marketing authorisation holder for Inhaled loxapine 10 mg in European Union?

Ferrer Internacional S.A. holds the EU marketing authorisation.